Collegium Pharmaceutical reported record quarterly net revenue for the third quarter 2026, driven by significant expansion in its ADHD franchise which now accounts for 36% of total revenue. While the legacy pain portfolio faced double-digit declines, the company surpassed consensus expectations for both top-line performance and adjusted earnings per share while reaffirming its full-year 2026 financial outlook.
Key Highlights
- JORNAY PM generated record quarterly net revenue of $51.9 million, representing a 24% year-over-year increase supported by a 19% rise in the prescriber base.
- AZSTARYS contributed $26.5 million in its first full quarter under ownership, reversing previous annual prescription declines to achieve 2% year-over-year growth.
- Pain portfolio revenues fell 18% year-over-year to $138.0 million, primarily due to a 44% decline in the Nucynta franchise and a 9% drop in Xtampza ER sales.